Gorbacheva V, Ayasoufi K, Fan R, Baldwin W M, Valujskikh A
Glickman Urological Institute and Department of Immunology, Cleveland Clinic, Cleveland, OH.
Am J Transplant. 2015 Feb;15(2):346-57. doi: 10.1111/ajt.12984. Epub 2014 Dec 12.
Donor-reactive memory T cells undermine organ transplant survival and are poorly controlled by immunosuppression or costimulatory blockade. Memory CD4 T cells provide CD40-independent help for the generation of donor-reactive effector CD8 T cells and alloantibodies (alloAbs) that rapidly mediate allograft rejection. The goal of this study was to investigate the role of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in alloresponses driven by memory CD4 T cells. The short-term neutralization of BAFF alone or BAFF plus APRIL synergized with anti-CD154 mAb to prolong heart allograft survival in recipients containing donor-reactive memory CD4 T cells. The prolongation was associated with reduction in antidonor alloAb responses and with inhibited reactivation and helper functions of memory CD4 T cells. Additional depletion of CD8 T cells did not enhance the prolonged allograft survival suggesting that donor-reactive alloAbs mediate late graft rejection in these recipients. This is the first report that targeting the BAFF cytokine network inhibits both humoral and cellular immune responses induced by memory CD4 T cells. Our results suggest that reagents neutralizing BAFF and APRIL may be used to enhance the efficacy of CD40/CD154 costimulatory blockade and improve allograft survival in T cell-sensitized recipients.
供体反应性记忆T细胞会破坏器官移植的存活,并且免疫抑制或共刺激阻断对其控制效果不佳。记忆性CD4 T细胞为供体反应性效应CD8 T细胞和同种异体抗体(alloAbs)的产生提供不依赖CD40的辅助,这些细胞和抗体可迅速介导同种异体移植排斥反应。本研究的目的是探讨B细胞活化因子(BAFF)和增殖诱导配体(APRIL)在由记忆性CD4 T细胞驱动的同种异体反应中的作用。单独短期中和BAFF或BAFF加APRIL与抗CD154单克隆抗体协同作用,可延长含有供体反应性记忆CD4 T细胞的受体心脏同种异体移植的存活时间。这种延长与抗供体alloAb反应的减少以及记忆性CD4 T细胞的再激活和辅助功能的抑制有关。额外去除CD8 T细胞并没有增强同种异体移植存活时间的延长,这表明供体反应性alloAbs介导了这些受体中的晚期移植物排斥反应。这是第一份关于靶向BAFF细胞因子网络可抑制记忆性CD4 T细胞诱导的体液和细胞免疫反应的报告。我们的结果表明,中和BAFF和APRIL的试剂可用于提高CD40/CD154共刺激阻断的疗效,并改善T细胞致敏受体的同种异体移植存活情况。